Introduction/Background The aim of this study was to evaluate the efficacy of Pembrolizumab for metastatic, recurrent, or persistent cervical carcinoma.

Methodology This is a retrospective review of medical records of patients with metastatic, recurrent, or persistent cervical carcinoma. Patients received pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision. Tumor assessment was performed every 9 weeks. The primary end point was objective response rate (ORR), assessed per Response Evaluation Criteria in Solid Tumors (version 1.1) by independent central radiologic review.

Results Of the 45 patients, 37 (82.2%), 7 (15.6%) and 1 (2.2%) had squamous-cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma, respectively. All the patients had prior platinum exposure and pelvic irradiation. All the patients had previously received one or more lines of chemotherapy for recurrent or metastatic disease. Recurrence included loco-regional (6/45, 13.3%), nodal (10/45, 22.2%), and distant site (29/45, 64.4%). Median follow-up was 8.5 months (range, 0 to 14 months). ORR was 33.3%, with nine complete and six partial responses. Possible Pembrolizumab-related adverse events included hypothyroidism (n=2/45, 4.4%), decreased appetite (n=3/45, 6.7%) and fatigue (n=3/45, 6.7%).

Conclusion Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer.

Disclosure Nothing to disclose.